Abstract: Recently, non-conventional odd-order statistics, especially the third-order cumulants (TOCs), have been introduced to direction-of-arrival (DOA) estimation based on third-order nested array ...

LONDON, Dec 18 (Reuters) - Zara has become the latest fast-fashion retailer to use AI to help create new images of real models in different outfits, speeding up the production process as part of an ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

A new Code Ninjas location is opening in Marlton this weekend, offering families a chance to explore the coding education center for children with hands-on activities. The new store is the 18th ...

Anthropic is starting to train its models on new Claude chats. If you’re using the bot and don’t want your chats used as training data, here’s how to opt out. Anthropic is prepared to repurpose ...

After posting flat revenue growth during FY24, Info Edge-backed edtech platform Coding Ninjas demonstrated 26.4% year-on-year growth in its operating revenue in the last fiscal year. Significantly, ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

The VP of engineering at a leading technology company stared at the quarterly adoption metrics with growing frustration. Twelve months after rolling out a state-of-the-art AI coding assistant—a tool ...

AI tools are widely used by software developers, but those devs and their managers are still grappling with figuring out how exactly to best put the tools to use, with growing pains emerging along the ...

AI-powered coding tools have become so popular over the past few months that almost every major tech company is either using one or making its own. Makers of these so-called “vibe-coding” tools are a ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...